Nantahala Capital Management’s Aprea Therapeutics APRE Stock Holding History

Nantahala Capital Management’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$165K	Hold	205,760	–	–	0.01%	154
2026 Q1	$157K	Hold	205,760	–	–	0.01%	150
2025 Q4	$176K	Hold	205,760	–	–	0.01%	149
2025 Q3	$303K	Hold	205,760	–	–	0.01%	149
2025 Q2	$348K	Hold	205,760	–	–	0.01%	148
2025 Q1	$420K	Hold	205,760	–	–	0.02%	134
2024 Q4	$677K	Hold	205,760	–	–	0.03%	123
2024 Q3	$566K	Hold	205,760	–	–	0.03%	122
2024 Q2	$837K	Hold	205,760	–	–	0.05%	109
2024 Q1	$1.38M	Buy	+205,760	New	+$1.28M	0.08%	95

Other funds holding APRE

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Nantahala Capital Management's APRE Position: Q2 2026 in Review

Nantahala Capital Management held its Aprea Therapeutics (APRE) position steady in Q2 2026 at 205,760 shares worth $165K. The position accounts for 0.01% of the portfolio, ranked #154.

Nantahala Capital Management first reported a position in APRE in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.38M in Q1 2024. 28 funds tracked by Wall St. Rank hold APRE as of Q2 2026.

Nantahala Capital Management held 205,760 shares of Aprea Therapeutics worth $165K as of Q2 2026.
Nantahala Capital Management left its Aprea Therapeutics share count unchanged in Q2 2026.
Aprea Therapeutics made up 0.01% of Nantahala Capital Management's portfolio in Q2 2026, its #154 holding.
Nantahala Capital Management first reported a position in Aprea Therapeutics in Q1 2024 and has held it in 10 quarters since.
Nantahala Capital Management's Aprea Therapeutics position peaked at $1.38M in Q1 2024.
28 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2026.

Based on Nantahala Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.